MAZE - mazetx.com Growth-Adjusted Payback Ratio

Symbol and logo of brand Maze Therapeutics Inc (MAZE)

The P/E dynamics relative to earnings growth for Maze Therapeutics Inc (MAZE) are supported by the implementation of AI platforms for bioscreening automation and target discovery. The value 0.00 indicates the current quote level. Revenues are based on the licensing of genetic discoveries for the treatment of rare pathologies. Stable demand for biotechnology renders the asset defensive, isolating Maze Therapeutics Inc (MAZE) from the impact of global macroeconomic crises.

MAZE - Maze Therapeutics, Inc. PEG Multiple over the range 02/01/2025 - 11/15/2026

Metric breakdowns and analytics for Maze Therapeutics (MAZE)

- current quotes and average value forecast:
General company analysis:MAZE Maze Therapeutics Corp
Mass-produced product of mazetx.com

To find fundamental support in Maze Therapeutics Inc (MAZE), it is essential to consider its synergy with behemoths such as GSK in the development of genetic drugs. By analyzing the PEG ratio, an investor compares the market value of earnings with the pace of business expansion: a value below one signals that the asset is undervalued relative to its growth, confirming the company's high investment attractiveness.

Competitors of Maze Therapeutics Inc

PEG Multiple Tempus (TEM)|PEG Multiple QGEN (Qiagen NV)|Growth-Adjusted Market Cap to Net Income Ionis (IONS)|repligen.com - PEG Multiple|Price to Earnings Adjusted for Growth Rate Avidity|CRSP (CRISPR Therapeutics Corp) - Price/Earnings to Growth Multiple|GeneDx Corp - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Ultragenyx|Price to Earnings Adjusted for Growth Rate beamtx.com BEAM|Price/Earnings to Growth Multiple SRPT (Sarepta Therapeutics, Inc.)|TWST - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio 10x TXG|Company Value to Earnings Growth Ratio NTLA (Intellia)|Stoke Corp - PEG Multiple|BLFS: Price/Earnings to Growth Ratio|WVE: PEG Multiple|Sionna Therapeutics, Inc. (SION) - PEG Multiple|Price/Earnings to Growth Ratio Prime Medicine, Inc.|TSHA (Taysha) - Company Value to Earnings Growth Ratio|Price/Earnings to Growth Multiple QURE (uniQure Pharma)|Growth-Adjusted Market Cap to Net Income meiragtx.com|Price/Earnings to Growth Ratio REGENXBIO RGNX|SLDB - Price/Earnings to Growth Multiple|Ocugen, Inc. - PEG Multiple|PACB (Pacific Biosciences of California) - Growth-Adjusted P/E Ratio|BNTC: PEG Multiple|DSGN - Growth-Adjusted Market Cap to Net Income|RCKT (Rocket Pharma) - PEG Multiple|Price/Earnings to Growth Ratio FDMT|Price/Earnings to Growth Ratio Lexeo Therapeutics, Inc. (LXEO)|Korro Bio Inc. - Growth-Adjusted P/E Ratio|editasmedicine.com - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income silence-therapeutics.com (SLN)|PRQR: Price/Earnings to Growth Multiple|Price to Earnings Adjusted for Growth Rate codexis.com|SGMO: PEG Multiple|Price to Earnings Adjusted for Growth Rate Nautilus Biotechnology Inc (NAUT)|Price/Earnings to Growth Multiple MGX|DTIL (Precision BioSciences) - Company Value to Earnings Growth Ratio|Price/Earnings to Growth Ratio Generation Bio Corp (GBIO)|Boundless Bio - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Exicure, Inc. XCUR|Growth-Adjusted Payback Ratio IMNN|PHIO - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Mustang Bio Inc MBIO|RNAZ: PEG Multiple|Growth-Adjusted P/E Ratio BNGO|APDN (Applied DNA Sciences Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Bluebird Bio BLUE|PEG Multiple IPA|Omega Therapeutics (OMGA) - Price to Net Income Growth Ratio|PEG Multiple OMIC (Singular Genomics Systems Inc)|Price to Net Income Growth Ratio Regulus Therapeutics Inc|SYRS - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio TBIO (Codex DNA)|TCON: PEG Multiple|UBX - Growth-Adjusted Market Cap to Net Income